Zobrazeno 1 - 10
of 99
pro vyhledávání: ''
Autor:
Maria Teresa Petrucci, Sara Petillo, Rossella Paolini, Chiara Pighi, Fabrizio Antonangeli, Alessandra Soriani, Cristina Capuano, Ricciarda Galandrini, Angela Santoni, Alessandra Zingoni, Rosa Molfetta, Cinzia Fionda, Marco Cippitelli, Abdelilah Mekhloufi
Publikováno v:
Cell Death and Disease, Vol 12, Iss 9, Pp 1-13 (2021)
Cell Death & Disease
Cell death and disease 12 (2021). doi:10.1038/s41419-021-04104-w
info:cnr-pdr/source/autori:Petillo, Sara; Capuano, Cristina; Molfetta, Rosa; Fionda, Cinzia; Mekhloufi, Abdelilah; Pighi, Chiara; Antonangeli, Fabrizio; Zingoni, Alessandra; Soriani, Alessandra; Petrucci, Maria Teresa; Galandrini, Ricciarda; Paolini, Rossella; Santoni, Angela; Cippitelli, Marco/titolo:Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition/doi:10.1038%2Fs41419-021-04104-w/rivista:Cell death and disease/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:12
Cell Death & Disease
Cell death and disease 12 (2021). doi:10.1038/s41419-021-04104-w
info:cnr-pdr/source/autori:Petillo, Sara; Capuano, Cristina; Molfetta, Rosa; Fionda, Cinzia; Mekhloufi, Abdelilah; Pighi, Chiara; Antonangeli, Fabrizio; Zingoni, Alessandra; Soriani, Alessandra; Petrucci, Maria Teresa; Galandrini, Ricciarda; Paolini, Rossella; Santoni, Angela; Cippitelli, Marco/titolo:Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition/doi:10.1038%2Fs41419-021-04104-w/rivista:Cell death and disease/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:12
Multiple Myeloma (MM) is an incurable hematologic malignancy of terminally differentiated plasma cells (PCs), where immune interactions play a key role in the control of cancer cell growth and survival. In particular, MM is characterized by a highly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a36c6bd94bd6ee4eb254b7ce50f2b8e
http://hdl.handle.net/11573/1568857
http://hdl.handle.net/11573/1568857
Autor:
Yuichi Sakamori, Naoki Nakajima, Toyohiro Hirai, Takahiro Tsuji, Akihiko Yoshizawa, Toshi Menju, Hiroaki Ozasa, Hitomi Ajimizu, Hiroshi Date, Hironori Yoshida, Yuto Yasuda, Tomoko Funazo, Masatoshi Yamazoe, Takashi Nomizo, Young Hak Kim
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 3, Pp 1-15 (2020)
Cell Death and Disease, Vol 11, Iss 3, Pp 1-15 (2020)
There have been few advances in the treatment of small-cell lung cancer (SCLC) because of the lack of targets. MCL1, a member of the anti-apoptotic BCL-2 family, may be a treatment target in several cancers, including SCLC. However, whether the expre
Autor:
Susumu Inamoto, Yoshiro Itatani, Gen Nishikawa, Jun Nakagawa, Rei Mizuno, Kenji Kawada, Yoshiharu Sakai, Ryotaro Ogawa, Kosuke Toda
Publikováno v:
Cell Death and Disease, Vol 10, Iss 4, Pp 1-13 (2019)
Cell Death & Disease
Cell Death & Disease
Mesenchymal stem cells (MSCs) are recruited from BM to the stroma of developing tumors, where they serve as critical components of the tumor microenvironment by secreting growth factors, cytokines, and chemokines. The role of MSCs in colorectal cance
Autor:
Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, Committee, International Working Group For Mds Molecular Prognostic
Publikováno v:
Leukemia
Leukemia, vol 33, iss 7
Leukemia, vol 33, iss 7
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d49797d5f17dd3791db8ac57149af6e
https://ora.ox.ac.uk/objects/uuid:e9f86a5f-8ced-4bb7-944f-fa27fc2c2541
https://ora.ox.ac.uk/objects/uuid:e9f86a5f-8ced-4bb7-944f-fa27fc2c2541
Autor:
P. le Coutre, Kapil N. Bhalla, Giuseppe Saglio, Oliver G. Ottmann, Dong-Kee Kim, Timothy P. Hughes, Jerry Radich, John V. Reynolds, Javier Pinilla-Ibarz, Michele Baccarani, Elias Jabbour, Norbert Gattermann, Hagop M. Kantarjian, Francis J. Giles, Jorge E. Cortes, Giovanni Martinelli, Richard A. Larson, Richard C. Woodman, Andreas Hochhaus
The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients with CML-CP (n = 321) were t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec341f0281c31baa704f50101d966d54
http://hdl.handle.net/10379/12051
http://hdl.handle.net/10379/12051
Autor:
Maarten C.C.M. Hulshof, Marja A. Boermeester, Jikke M.T. Omloo, W. L. Vervenne, Marinke Westerterp, René Lutter, J. Jan B. van Lanschot, Theo A. Out
Publikováno v:
Cancer immunology, immunotherapy, 57(12), 1837-1847. Springer Science and Business Media Deutschland GmbH
BACKGROUND: To compare immune responses following neoadjuvant chemoradiation therapy in combination with hyperthermia plus surgery to those induced by surgery alone in patients with oesophageal cancer. METHODS: Thirty-two patients with histopathologi
Autor:
Helga B. Salvesen, Aarskog Nina K, S E Monstad, Christian A. Vedeler, Jane Kristin Nøstbakken, Bjørn Ivar Haukanes, Tilo Wolf Eichler, Mette Haugen, Cecilie Totland, Sverre Mørk
Publikováno v:
Cancer Immunology, Immunotherapy
Paraneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied
Autor:
Peter Gedeon, Håkan Griph, Ana Carneiro, Viktoria Bergqvist, Marija Kopljar, Sara Kinhult, Erik Hertervig, Jan Marsal
Publikováno v:
Cancer Immunology, Immunotherapy
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since
Publikováno v:
International Journal of Colorectal Disease
Background Interleukin-8 (IL-8) also referred to as CXCL8, a member of the CXC chemokine family that attracts neutrophils and other leukocytes, has been associated with cancer. Angiogenesis is a prime regulator of tumour expansion and data support th
Autor:
Mads Hald Andersen, Cathrin Ritter, Per thor Straten, Jürgen C. Becker, Rikke Sick Andersen, Inge Marie Svane, Rikke Bæk Sørensen
Publikováno v:
Cancer Immunology, Immunotherapy
With the aim to identify cyclin B1-derived peptides with high affinity for HLA-A2, we used three in silico prediction algorithms to screen the protein sequence for possible HLA-A2 binders. One peptide scored highest in all three algorithms, and the h